Results 1 to 10 of about 13,099 (221)

Detection of two alternative bcr/abl mRNA junctions and minimal residual disease in Philadelphia chromosome positive chronic myelogenous leukemia by polymerase chain reaction [PDF]

Blood, 1989
The Philadelphia (Ph′) chromosome in chronic myelogenous leukemia (CML) results in fusion of the bcr gene and c-abl oncogene, which transcribes into two types of chimeric bcr/abl mRNAs: the L-6 junction and the K-28 junction. By means of a highly sensitive assay, combination of reverse transcription and polymerase chain reaction (RT/PCR), we analyzed ...
M S, Lee, A, LeMaistre, H M, Kantarjian, M, Talpaz, E J, Freireich, J M, Trujillo, S A, Stass   +6 more
openaire   +3 more sources

Mutational analysis of T315I in patients with chronic myeloid leukemia who did not respond to second-generation tyrosine kinase inhibitors

Iraqi Journal of Hematology, 2020
BACKGROUND: Chronic myelogenous leukemia (CML) is a hematological stem cell disorder that associates with mutations in BCR-ABL. Although mutations identified in more than 30 different amino acids, the highest degree of resistance was associated with ...
Riyam Qusay Ibrahim Al-Jadir, Jaffar Nouri Alalsaidissa   +1 more
doaj   +1 more source

Allogeneic stem cell transplant for chronic myeloid leukemia as a still promising option in the era of the new target therapy [PDF]

Vojnosanitetski Pregled, 2012
Background/Aim. Introducing tyrosine kinase inhibitors (TKIs) has essentially changed curative approach, to be precise, clearly improved treatment efficacy for chronic myeloid leukemia (CML).
Stamatović Dragana, Balint Bela, Tukić Ljiljana, Elez Marija, Tarabar Olivera, Todorović Milena, Todorić-Živanović Biljana, Ostojić Gordana, Tatomirović Željka, Marjanović Slobodan, Malešević Milomir   +10 more
doaj   +1 more source

Is There an Entity of Chemically Induced BCR-ABL–Positive Chronic Myelogenous Leukemia?

The Oncologist, 2008
Abstract Learning Objectives After completing this course, the reader will be able to: Distinguish the exogenous causes of acute and chronic myelogenous leukemia.Discuss the evidence establishing the exogenous causes of secondary leukemia.Describe the relationship of radiation and chemical exposure to
openaire   +2 more sources

Comparative Response of Canine and Human Osteosarcoma Tumour Cell Lines to Molecularly Targeted Anticancer Agents at Clinically Relevant Exposures With Analysis of Genomic Biomarkers

Veterinary and Comparative Oncology, EarlyView.
ABSTRACT Osteosarcoma (OSA) is a primary bone tumour occurring in children but is also prevalent in large breed dogs. Canine OSA (cOSA) has long been viewed as analogous to human OSA (hOSA) with cOSA serving as a surrogate for development of therapeutic approaches to treat the rarer human form.
Daniel L. Gustafson, Kala A. Early, Maritza A. Morales, Klaudia A. Poplawski, Sunetra Das, Dawn L. Duval   +5 more
wiley   +1 more source

Serine and proline-rich ligands enriched via phage-display technology show preferential binding to BCR/ABL expressing cells

Hematology/Oncology and Stem Cell Therapy, 2014
BACKGROUND AND OBJECTIVES: Despite the use of targeted therapy, chronic myelogenous leukemia (CML) currently remains incurable with drug therapy, with patients requiring life-long treatment.
Karen Shires, Iva Shankland, Shaheen Mowla, Samuel Njikan, Jai Jaymacker   +4 more
doaj   +1 more source

Factors associated with achievement and durability of cytogenetic response in patients with chronic myeloid leukemia treated with imatinib [PDF]

Vojnosanitetski Pregled, 2011
Background/Aim. Imatinib mesylate, a selective Bcr-Abl tyrosine kinase inhibitor, has revolutionized the treatment of Bcr-Abl positive chronic myeloid leukemia and become the standard of care for this disease.
Ćojbašić Irena, Mačukanović-Golubović Lana   +1 more
doaj   +1 more source

Monitoring of BCR-ABL levels in chronic myeloid leukemia patients treated with imatinib in the chronic phase: the importance of a major molecular response

Revista Brasileira de Hematologia e Hemoterapia, 2011
BACKGROUND: Real time PCR has become the most common technique to monitor BCR-ABL transcript levels of patients treated with kinase inhibitors. The aim of this study was to evaluate BCR-ABL levels of chronic myeloid leukemia patients treated with ...
Melissa Pereira Machado, Juarez Pires Tomaz, Irene Lorand-Metze, Cármino Antonio de Souza, Afonso Celso Vigorito, Marcia Torresan Delamain, Israel Bendit, Noemi Farah Pereira, Katia Borgia Barbosa Pagnano   +8 more
doaj   +1 more source

Post‐translational Modifications in Proteins: Prediction Methods, Biological Functions, and Diseases

MedComm, Volume 7, Issue 4, April 2026.
Posttranslational modifications (PTMs) serve as rapid and reversible molecular switches that reshape protein activity, stability, and interactomes, thereby governing virtually all physiological cues ranging from signal transduction to epigenetic memory. Mass spectrometry‐based proteomics has substantially expanded our understanding of PTM emergence and
Shuning Zhang, Jingmin Li, Meihuan Chen, Hailong Huang   +3 more
wiley   +1 more source

Recommendations from a Portuguese Expert Group for Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Patients in Clinical Practice

Acta Médica Portuguesa, 2019
Until recently, the main goal of chronic myeloid leukemia therapy was disease control with the best overall survival, which required lifelong treatment.
Antonio Almeida, Francesca Pierdomenico, Blanca Polo Guerrero, Filipa Saraiva, Ana Montalvão, Jorge Coutinho, Mário Mariz, Teresa Melo, Maria João Santos, Alexandra Pereira, Nuno Cerveira   +10 more
doaj   +1 more source